Skip to main content

Trovagene Gets $15M Credit Facility to Fund Cancer Monitoring Tech Development, Commercialization

NEW YORK (GenomeWeb) – Trovagene has secured a $15 million unrestricted debt facility from Silicon Valley Bank and Oxford Finance, the company said on Tuesday.

The San Diego-based firm will use the capital to support development and commercialization of its urine-based cell-free oncogene mutation cancer monitoring technology.

Trovagene said it expects to report holding roughly $35 million in cash and cash equivalents for the second fiscal quarter, which ended on June 30. It reported $22.9 million in cash holdings at the end of the first quarter.

"We continue to advance our proprietary cancer monitoring platform and the application of our technology in clinical settings," Trovagene CFO Stephen Zaniboni said in a statement. "Recent progress includes clinical study results presented at ASCO 2014 and a reference in clinical consensus guidelines for the treatment of certain histiocytic disorders associated with BRAF V600E mutations."

Earlier this week, Trovagene said it partnered with Northwestern University's Robert H. Lurie Comprehensive Care Center and Northwestern Medicine Developmental Therapeutics Institute to assess the clinical utility of its oncogene-based disease management technology for monitoring patients during treatment and to measure outcomes.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.